PUBLICATIONS AND PresentationS
Discover the main highlights of our industry in our latest publications.
Quick links
Presentation
Publication
Key Economic & Value Considerations in the US
Market for PPTs
Market for PPTs
Key Economic & Value Considerations for PDMPs
in Europe
in Europe
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mar 15, 2022
PPTA’s Plasmavigilance Program: Adverse events among U.S. Source plasma donors
All
Publication
https://plasmaprotein.sharepoint.com/sites/COMMS/cd/Forms/AllItems.aspx?id=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29%2FSource%5FSpring%202022%2Epdf&parent=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29&p=true&ga=1
Mar 15, 2022
PPTA’s Plasmavigilance Program: Adverse events among U.S. Source plasma donors
All
Publication
https://plasmaprotein.sharepoint.com/sites/COMMS/cd/Forms/AllItems.aspx?id=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29%2FSource%5FSpring%202022%2Epdf&parent=%2Fsites%2FCOMMS%2Fcd%2FSource%20Magazine%2FPublication%20%28permanent%29&p=true&ga=1
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Sep 1, 2021
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64524317f82dbf9d9297bca9_Plasma_core_policy_report_2022web.pdf
Sep 1, 2021
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
In the coming decade European countries will see an increased need for plasma-derived medicines to treat their patients for a range of rare diseases and critical medical conditions. While demand for blood components for transfusion remains relatively stable, a European Commission survey (2014) shows that demand for plasma derivatives is increasing by some 6% per year.
All
Publication
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/64524317f82dbf9d9297bca9_Plasma_core_policy_report_2022web.pdf
No results found